Clinical Trials on Orthomyxovirdae

Total 2021 results

National Institute of Allergy and Infectious Diseases...

Completed

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | Orthomyxovirdae

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Australia, New Zealand
Sanofi Pasteur, a Sanofi Company

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Italy, Belgium, France, Lithuania
Sanofi Pasteur, a Sanofi Company

Completed

Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Spain, France, Lithuania, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Czech Republic, Lithuania, Belgium
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety Study of Avian Flu Vaccine

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Influenza

United States
Fraunhofer, Center for Molecular Biotechnology

Completed

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

Healthy

United States
Vaxart

Completed

Immunogenicity of ND1.1 by Delivery Directly to the Ileum (ICC H5)

Avian Influenza

United States
Intercell USA, Inc.

Completed

Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine

Healthy

Austria, Belgium
Fab'entech

Completed

Safety and Pharmacokinetics Study of FBF001

Avian Influenza
University of Minnesota

Recruiting

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

Solid Organ Transplant

United States
Nanjing Zenshine Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects (QTc-ZX-7101A)

Influenza, Human

China
Seqirus

Completed

Efficacy Study With QIVc in Pediatric Subjects

Influenza, Human

Bangladesh, Bulgaria, Czechia, Estonia, Honduras, Latvia, Malaysia, New Zealand, Pakistan, Philippines, Poland, Romania, Thailand, Ukraine, South Africa
Poolbeg Pharma plc

Completed

Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses

Influenza, Human

Netherlands
Novavax

Terminated

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Influenza, Human

United States
University of Pennsylvania
Geisinger Clinic

Completed

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates

Influenza, Human

United States
Seqirus

Completed

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age

Influenza, Human

Australia, Estonia, Finland, Lithuania, Philippines, Poland, Spain, Thailand
Daiichi Sankyo Co., Ltd.

Completed

A Multinational Phase III Study of CS-8958 (MARVEL) (MARVEL)

Influenza, Human

Taiwan, Japan, Korea, Republic of, China
AIM ImmunoTech Inc.

Terminated

Safety Study of FluMist With and Without Ampligen

Influenza, Human

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

Influenza, Human

United States
GlaxoSmithKline

Completed

Relenza® Sentinel Site Monitoring Program in Japan (SSMP)

Influenza, Human
Green Cross Corporation

Completed

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older

Influenza, Human

Korea, Republic of
GlaxoSmithKline

Completed

Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults

Influenza, Human

China
Mahidol University

Completed

Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers

Preventive Avian Flu

Thailand
Nanjing Zenshine Pharmaceuticals

Not yet recruiting

Substance Balance Study of [14C]ZX-7101A in Healthy Adult Male Subjects in China

Influenza, Human
Seqirus

Active, not recruiting

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Influenza, Human

Philippines, United States, Germany, Pakistan, Canada, Estonia, Denmark, United Kingdom
Codagenix, Inc

Active, not recruiting

Intramuscular CodaVax-H1N1 in Healthy Adults

Influenza, Human

Australia
University of Houston
National Institute on Aging (NIA)

Completed

Resistance Exercise to Improve Flu Vaccine for Older Adults

Influenza, Human

United States
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
Biomedical Advanced Research and Development Authority
Rho, Inc.

Completed

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

Influenza, Human

United States
SGS Life Sciences, a division of SGS Belgium NV

Completed

A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy Volunteers

Influenza, Human
Green Cross Corporation

Completed

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects

Influenza, Human

Korea, Republic of
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Vaccine for Prevention of Bird Flu

Influenza, Human

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

Influenza, Human

United States
Green Cross Corporation

Unknown

A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults

Influenza, Human
Mahidol University

Completed

Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group.

Influenza, Human

Thailand
NanoPass Technologies Ltd

Completed

A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines (NANOVAX)

Influenza, Human
Chronic Obstructive Pulmonary Disease Trial Network...
The Novo Nordic Foundation

Not yet recruiting

Vaccine Pandemic Preparedness Through Airway Immunology Characterization (VAXXAIR)

Influenza, Human

United Kingdom, Denmark
Novavax

Completed

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

Influenza, Human

United States
University of Pennsylvania

Completed

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy

Influenza, Human

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years

Influenza, Human

Canada
University Medical Centre Ljubljana

Completed

Prophylactic Treatment With Oseltamivir

Influenza, Human

Slovenia
Il-Yang Pharm. Co., Ltd.

Completed

Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults

Influenza, Human
Eurocine Vaccines AB

Completed

Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

Influenza, Human

Sweden

Clinical Trials on Orthomyxovirdae

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations